TRACON Pharmaceuticals WKN: A2PU7C ISIN: US89237H2094 Forum: Aktien Thema: Hauptdiskussion
Kommentare 123
Schorsch11,
01.01.2020 17:25 Uhr
0
RS wurde am 8. November durchgeführt
Following the special meeting of stockholders, the Board of Directors approved a 1-for-10 reverse stock split.
The effective time of the reverse stock split was 5:01 p.m. ET on November 7, 2019. The Company's shares will begin trading on a split-adjusted basis commencing upon market open on November 8, 2019.
Schorsch11,
01.01.2020 17:20 Uhr
0
78 Patente
https://patentscope.wipo.int/search/en/result.jsf?_vid=P12-K4VI9Y-45109
20 klinische Studien
https://clinicaltrials.gov/ct2/results?cond=&term=Tracon+Pharmaceuticals&cntry=&state=&city=&dist=
Schorsch11,
01.01.2020 17:18 Uhr
0
Cash: 19.1mio$
Burn: 2.2mio$/month
finanziert bis Mai 2020
Schorsch11,
01.01.2020 17:17 Uhr
0
TRACON Pharmaceuticals, 3D Medicines And Jiangsu Alphamab Announce Partnership For Development Of Subcutaneous PD-L1 Single-Domain Antibody In Soft Tissue Sarcoma
Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT
Envafolimab represents a potential best-in-class PD-L1 inhibitor that is injectable subcutaneously without the need for an adjuvant
Envafolimab has been dosed in more than 650 patients in the U.S., China and Japan, and is currently being evaluated in registrational trials in China in patients with high microsatellite instability (“MSI-H”) cancer and biliary tract cancer
Immune checkpoint inhibitors targeting the PD-1 or PD-L1 pathway have demonstrated activity in multiple soft tissue sarcoma subtypes, including undifferentiated pleomorphic sarcoma (UPS)
TRACON intends to initiate a registration enabling study of envafolimab in the sarcoma subtype of UPS in 2020
https://traconpharma.gcs-web.com/news-releases/news-release-details/tracon-pharmaceuticals-3d-medicines-and-jiangsu-alphamab
Schorsch11,
01.01.2020 17:08 Uhr
0
WL
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | für alle, die es ehrlich meinen beim Traden. | ||
2 | PAYPAL Hauptdiskussion | -2,79 % | |
3 | BIOXCEL THERAPEUT DL-,001 Hauptdiskussion | -10,76 % | |
4 | Dax Prognose | +0,33 % | |
5 | Trading- und Aktien-Chat | ||
6 | Canopy Hauptforum | -3,67 % | |
7 | Jaguar Health für Investierte und Interessierte | -9,26 % | |
8 | Phunware ab 27.02.24 RS | +4,42 % | |
9 | Basin Uranium Hauptdiskussion | -25,13 % | |
10 | Das neue Dax Prognose Forum | +0,33 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | BIOXCEL THERAPEUT DL-,001 Hauptdiskussion | -10,76 % | |
2 | PAYPAL Hauptdiskussion | -2,79 % | |
3 | Canopy Hauptforum | -3,67 % | |
4 | Jaguar Health für Investierte und Interessierte | -9,26 % | |
5 | Phunware ab 27.02.24 RS | +4,42 % | |
6 | Basin Uranium Hauptdiskussion | -25,13 % | |
7 | FREYR BATTERY | -1,60 % | |
8 | XIAOMI CORP. CL.B Hauptdiskussion | +6,43 % | |
9 | HELLOFRESH SE INH O.N. Hauptdiskussion | -1,46 % | |
10 | HYMC | +1,76 % | Alle Diskussionen |